Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Audentes Therapeutics, Inc. (BOLD)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/31/2022 |
3
| Audentes Therapeutics, Inc. (10% Owner) has filed a Form 3 on Taysha Gene Therapies, Inc. |
| 10/31/2022 |
SC 13D
| Audentes Therapeutics, Inc. reports a 11.6% stake in TAYSHA GENE THERAPIES, INC. |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/11/2020 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/05/2020 |
SC 13G/A
| BlackRock Inc. reports a 8% stake in Audentes Therapeutics, Inc. |
| 01/27/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 01/21/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/21/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/15/2020 |
4
| Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 183,384 shares
@ $60, valued at
$11M
Disposed/sold 3,829 options to buy
@ $2.7649, valued at
$10.6k
Disposed/sold 6,263 options to buy
@ $9.4988, valued at
$59.5k
Disposed/sold 73,781 options to buy
@ $15.26, valued at
$1.1M
Disposed/sold 75,000 options to buy
@ $27.39, valued at
$2.1M
Disposed/sold 65,000 options to buy
@ $24.74, valued at
$1.6M
|
|
| 01/15/2020 |
4
| Smith Julie (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Disposed/sold 18,000 options to buy
@ $17.85, valued at
$321.3k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Schuetz Thomas J. (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 89,695 shares
@ $60, valued at
$5.4M
Disposed/sold 18,086 options to buy
@ $0.7804, valued at
$14.1k
Disposed/sold 5,605 options to buy
@ $2.1852, valued at
$12.2k
Disposed/sold 9,000 options to buy
@ $15.03, valued at
$135.3k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Patterson Matthew R (CEO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 261,458 shares
@ $60, valued at
$15.7M
Unknown transaction of 171,814 shares
@ $60, valued at
$10.3M
Disposed/sold 143,569 options to buy
@ $9.4988, valued at
$1.4M
Disposed/sold 188,334 options to buy
@ $15.26, valued at
$2.9M
Disposed/sold 225,000 options to buy
@ $27.39, valued at
$6.2M
Disposed/sold 177,450 options to buy
@ $24.74, valued at
$4.4M
|
|
| 01/15/2020 |
4
| Mosbrooker Eric (SVP, Chief Commercial Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 26,919 shares
@ $60, valued at
$1.6M
Disposed/sold 87,750 options to buy
@ $22.01, valued at
$1.9M
|
|
| 01/15/2020 |
4
| Morrison Scott W (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Disposed/sold 33,635 options to buy
@ $9.4988, valued at
$319.5k
Disposed/sold 9,000 options to buy
@ $15.03, valued at
$135.3k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Meltz Mark A (SVP, General Counsel) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 32,705 shares
@ $60, valued at
$2M
Disposed/sold 104,000 options to buy
@ $37.26, valued at
$3.9M
|
|
| 01/15/2020 |
4
| LANGE LOUIS G (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 265,799 shares
@ $60, valued at
$15.9M
Unknown transaction of 13,678 shares
@ $60, valued at
$820.7k
Unknown transaction of 32,343 shares
@ $60, valued at
$1.9M
Unknown transaction of 3,555 shares
@ $60, valued at
$213.3k
Disposed/sold 18,000 options to buy
@ $15.03, valued at
$270.5k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Jarrett Jennifer (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Disposed/sold 18,000 options to buy
@ $14.7, valued at
$264.6k
Disposed/sold 9,000 options to buy
@ $0
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Holles Natalie C. (President and COO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 104,439 shares
@ $60, valued at
$6.3M
Disposed/sold 110,703 options to buy
@ $2.7649, valued at
$306.1k
Disposed/sold 548 options to buy
@ $9.4988, valued at
$5.2k
Disposed/sold 40,883 options to buy
@ $15.26, valued at
$623.9k
Disposed/sold 93,109 options to buy
@ $27.39, valued at
$2.6M
Disposed/sold 25,000 options to buy
@ $36.39, valued at
$909.8k
Disposed/sold 50,105 options to buy
@ $24.74, valued at
$1.2M
|
|
| 01/15/2020 |
4
| Goldberg Mark Alan (Director) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 1,500 shares
@ $60, valued at
$90k
Disposed/sold 18,000 options to buy
@ $33.91, valued at
$610.4k
Disposed/sold 4,500 options to buy
@ $38, valued at
$171k
Disposed/sold 10,000 options to buy
@ $38.65, valued at
$386.5k
Disposed/sold 16,200 options to buy
@ $24.74, valued at
$400.8k
|
|
| 01/15/2020 |
4
| Conner Edward R. (SVP, Chief Medical Officer) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Unknown transaction of 24,584 shares
@ $60, valued at
$1.5M
Disposed/sold 90,000 options to buy
@ $36.08, valued at
$3.2M
|
|
| 01/15/2020 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 01/15/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/15/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/15/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/15/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/15/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/15/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/15/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/15/2020 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 01/15/2020 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/15/2020 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/10/2020 |
4
| Soloway Thomas P (Executive Vice President, CFO) has filed a Form 4 on Audentes Therapeutics, Inc.|
Txns:
| Exercised 144,669 options to buy
@ $2.7649, valued at
$400k
Exercised 6,219 options to buy
@ $15.26, valued at
$94.9k
|
|
|
|
|